Brean, Murray & Carret Downgrades American Oriental Bioengineering To Hold, Removes PT

March 15, 2011 8:05 AM | 8 seconds read |

Brean, Murray Carret & Co. has downgraded American Oriental Bioengineering AOB from Buy to Hold and has removed its $3.70 price target.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst Ratingsamerican oriental bioengineeringBrean Murray Carret & CompanyConsumer StaplesPersonal Products
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!